Tenderwize
Retour à la recherche

Discount Agreements Dolutegravir and Rilpivirin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2028 · 644 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dolutegravir und Rilpivirin, ATC J05AR21

60/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

40 / 100

Facteurs de risque

Open-house model is not subject to procurement law; limited legal remedies via social courts.

No minimum or maximum volume guaranteed; contracts can be terminated with one month's notice.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2028
  • Provision of pharmaceutical products containing Dolutegravir and Rilpivirin
  • Entering non-exclusive discount agreements with AOK Bayern
Afficher le résumé complet

This is an open-house model (not a formal tender) by AOK Bayern for non-exclusive discount agreements on Dolutegravir and Rilpivirin (ATC J05AR21). All eligible pharmaceutical companies can join at any time until 03.06.2028. Contracts run from 01.08.2026 to 31.07.2028. No estimated value is provided. Eligibility requires a signed declaration of reliability. Submission can be in paper (two originals) or electronic with qualified electronic signature. The notice explicitly states this is not subject to procurement law.

Risques

Open-house model is not subject to procurement law; limited legal remedies via social courts.

No minimum or maximum volume guaranteed; contracts can be terminated with one month's notice.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Contract duration: 01.08.2026 – 31.07.2028

Eligibility

  • Open-house model – no competition, all eligible companies can join

Administrative

  • Rolling admission: submit by 3rd of month for start next month

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria – all eligible participants are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Discount Agreements Dolutegravir and Rilpivirin

Non-exclusive open-house discount agreements for pharmaceutical products with active substances Dolutegravir and Rilpivirin (ATC J05AR21). Contracts are identical for all participants.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria – all eligible participants are accepted.

Date limite

Deadline Jun 03, 2028

Détails de la procédure

Date de publication
14 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
407096-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30